|
Booming US Generic Drug Market
By Shushmul Maheshwari
RNCOS E-Services Pvt. Ltd.
Email: press@rncos.com
http://www.rncos.com/
Monday - November 2, 2009
Category: Investment, Biotech
The growth of generics markets in the US is in full swing. Realizing its importance in minimizing the healthcare cost, government is also taking initiative to promote this market. Over the past ten years (1999-2008), the generic drugs have saved US$ 734 Billion for the American healthcare system.
With patents of several blockbuster drugs expiring in next 3-4 years, generic drugs sector of the US presents a promising and availing opportunity for big pharma players from Europe, Asia and other regions to invest.
The US generics market is forecasted to grow at a CAGR of around 9.2% during 2010-2012, says our recent research report "Booming US Generic Drug Market".
Currently, the market is characterized by the emergence of new products as patents of branded drugs are getting expired. This trend is likely to continue in next few years. Anticipating the future growth, big pharma players are making deals with some generics manufactures from Asian countries, like India, to access their products and market them in the US.
We have discovered that generics market is expected to grow more strongly due to global economic downturn. The people are buying more generic products in order to cut their healthcare cost. Although several challenges, such as price erosion and litigations from branded manufacturers, may hamper the growth, the overall growth prospects of the market remain good. In this regard, our report provides rational analysis of various factors which will drive this market segment over the forecasted period.
The report also provides extensive information on the generics market in the US, besides discussing the emerging trends like contract manufacturing and biogenerics. Thus, it provides valuable information to pharmaceuti cal & generics companies and investors looking to enter this market. Analysis and statistics regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed to provide clients a comprehensive overview of the market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM589.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. We are a team of industry experts who analyze data collected from credible sources. We provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
Published at the www.InvestorIdeas.com Investing, Research and Industry Articles News Feed - Investorideas.com Financial Article Feed
Become an Investorideas.com Member and access some of our best investor research tools: Investing in Renewable Energy, Environment and Water Stocks
Become an Investorideas.com Member - Gain login access to 8 global stock directories including renewable energy stocks directory, environment stocks, water stocks, fuel cell stocks, biotech stocks, defense stocks, natural gas stocks, oil and gas stocks as well as the Insiders Corner investor newsletter covering insider buying trends on small cap stocks.
Investors: Sign up for free newsletter, stock and sector news alerts at Investorideas.com. Or publish your own stock picks and share your investing and trading ideas with other investors. Publish your investor ideas today!
www.InvestorIdeas.com - Big Ideas for the Small Cap Investor
Disclaimer: The views and opinions expressed in the research published are those of the individual companies and writers and not necessarily those of Investorideas.comŽ, or any of the industry sector portals . At the time of publication, writers may hold positions in the stocks or companies mentioned.
Investorideas.comŽ or any of the industry sector portals cannot assure accuracy of the research presented. Investors are encouraged to research and verify facts and under no circumstances is Investorideas.comŽ endorsing the content as a recommendation to buy or sell stock.
|
